ALC - Alcon Inc.
Chart Events
Slow Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 58.38 |
| Open | 58.77 |
| Bid | 58.76 x 1000 |
| Ask | 63.38 x 900 |
| Day's Range | 58.61 - 59.08 |
| 52 Week Range | 39.37 - 65.37 |
| Volume | 892,424 |
| Avg. Volume | 1,459,077 |
| Market Cap | 28.678B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.45 |
Fair Value
Related Research
- Insider Monkey
Hedge Funds Aren’t Done Buying Alcon Inc. (ALC)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- Business Wire
Alcon Prices US$750.0 Million Senior Notes Offering
Alcon prices US$750.0 million senior notes offering
- Motley Fool
Alcon Inc (ALC) Q1 2020 Earnings Call Transcript
Joining me on today's call are David Endicott, our Chief Executive Officer; and Tim Stonesifer, our Chief Financial Officer. Accordingly, you should not place undue reliance on any forward-looking statements.
- GuruFocus.com
Dow Jones Falls Over 500 Points on Wednesday
Alcon jumps on the back of strong first-quarter results Continue reading...
- Business Wire
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual American Society of Cataract and Refractive Surgery 2020 Annual Meeting
Alcon to Highlight Robust Scientific Program Showcasing Latest Innovations at Virtual ASCRS 2020
- Business Wire
Alcon Shareholders Approve All Proposed Resolutions at the 2020 Annual General Meeting
Alcon shareholders approve all proposed resolutions at the 2020 Annual General Meeting
- Benzinga
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech stocks that hit 52-week lows April 6) * BIOLASE Inc (NASDAQ: BIOL) * China SXT Pharmaceuticals Inc (NASDAQ: SXTC) * ENDRA Life Sciences Inc (NASDAQ: NDRA) * Global Cord Blood Corp (NYSE: CO) * ImmuCell Corporation (NASDAQ: ICCC) * IMMURON LTD/S ADR (NASDAQ: IMRN) * Menlo Therapeutics Inc (NASDAQ: MNLO) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) * Merus NV (NASDAQ: MRUS) * Millendo Therapeutics Inc (NASDAQ: MLND) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) * Obalon Therapeutics Inc (NASDAQ: OBLN) * Quest Diagnostics Inc (NYSE: DGX) (said it has performed 550,000 COVID-19 tests) * Second Sight Medical Products Inc (NASDAQ: EYES)Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced they have finalized the planned restructuring related to cholesterol drug Praluent. Effective April 1, Sanofi will have the sole responsibility for Praluent outside the U.S., while Regeneron assumes the sole responsibility in the U.S. The companies entered into an agreement to support manufacturing needs in the near term.The intention to restructure the antibody collaboration was announced in December 2019. Crinetics Reports Positive Results In Midstage Study Of Paltusotine Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) announced positive interim results from the ongoing ACROBAT Edge Phase 2 trial that is evaluating the safety and efficacy of paltusotine in patients with acromegaly who have not achieved normal IGF-1 levels despite stable therapy with a somatostatin receptor ligands, or SRL, or with a SRL in combination with a dopamine agonist.The company said enrollment in the ACROBAT Edge study is complete, with topline data expected in the fourth quarter of 2020.The company also said it plans to advance paltusotine for acromegaly into Phase 3 trials in the first half of 2021 and into Phase 2 trials for patients with neuroendocrine tumors who suffer from carcinoid syndrome.See also: The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations AIM ImmunoTech To Test Ampligen Delivery Using Vaping Device For Coronavirus In China AIM ImmunoTech Inc (NYSE: AIM) said it has entered into a material transfer and research agreement with vaping device maker Shenzhen Smoore Technology to research in China the efficacy of Smoore's inhalation delivery device using Ampligen.Ampligen is AIM's lead drug which has been approved for myalgic encephalomyelitis and chronic fatigue syndrome in Argentina.AIM said it believes Ampligen has potential as a prophylactic/early-onset therapeutic against COVID-19 caused by the new coronavirus, as it has yielded 100% protective efficacy against SARS-CoV-1 viral infection in duplicate experiments using a mouse model in U.S.View more earnings on IBBThe stock was down 0.35% at $2.84 in Tuesday's premarket session. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Natus Lowers Q1 Revenue Guidance Due To COVID-19 Impact Natus Medical Inc (NASDAQ: NTUS) announced preliminary first-quarter revenue of $109 million to $110 million, lower than its previous guidance of $113 million to $117 million. The company blamed the shortfall relative to the guidance to the COVID-19 pandemic. The company also withdrew its 2020 guidance.In premarket trading Tuesday, the stock was slipping 2.17% to $22.25.Announcements On COVID-Related Impacts Alcon AG (NYSE: ALC) said it is withdrawing its 2020 guidance. The company also said it has withdrawn the dividend proposal to be discussed at its May 6 annual general meeting. The company plans to delay dividend initiation until 2021.The stock was down 1.41% at $51.58 in Tuesday's premarket session. Morphosys Ag (NASDAQ: MOR) said it is temporarily pausing enrollment and screening of patients in the M-PLACE study with MOR202. The company said it plans to continue enrollment of patients in studies with the potential for significant benefit in life-threatening conditions.As of now, the company said it is maintaining its previously communicated 2020 guidance with respect to corporate milestones.Zimmer Biomet Holdings Inc (NYSE: ZBH) lowered its first-quarter revenue growth guidance to negative 9.5%-10.5%, citing a significant and sudden decline in elective procedure volume due to the COVID-19 pandemic. Analysts, on average, currently expect a 2.7% year-over-year revenue decline. The company also withdrew its full-year guidance.Penumbra Inc (NYSE: PEN) pre-announced first-quarter revenue of $137 million to $137.3 million, below the consensus estimate of $138.08 million. The company also withdrew its guidance.On The Radar Earnings * AngioDynamics, Inc. (NASDAQ: ANGO) (after the close)Related Link: Co-Diagnostics COVID-19 Test Gets FDA Emergency Use Authorization See more from Benzinga * The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO * The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Alcon Inc. (ALC)
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- Business Wire
Alcon Announces European Launch of Vivity, the Only Presbyopia-correcting Intraocular Lens With X-WAVE Technology
Alcon announces European launch of Vivity, the only presbyopia-correcting intraocular lens with X-WAVE technology
- Business Wire
Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
Alcon Partners with Actress Cheryl Ladd to Share Her Cataract Journey, Renewed Vision and PanOptimist Story
- GuruFocus.com
3 Low Price-Book Stocks for Value Investors to Consider
Bank of America tops the list Continue reading...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Alcon Inc. (ALC)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Insider Monkey
Hedge Funds Love Electronic Arts (EA) Way More Than These Stocks
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]
- GuruFocus.com
Top 5 Buys of George Soros' Firm in 3rd Quarter
Firm of Hungarian-born guru releases portfolio Continue reading...
- GuruFocus.com
David Rolfe Adds 2 Tech Stocks to Portfolio in 3rd Quarter
Guru invests in Nvidia, CDW Continue reading...
- GuruFocus.com
Invesco European Growth Fund Starts 1 Position, Boosts 5 Others in 3rd Quarter
Fund releases quarterly portfolio as UK and European Union leaders negotiate Brexit deal Continue reading...
- Insider Monkey
Here is What Hedge Funds Think About Alcon Inc. (ALC)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Benzinga
The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder ...
- Benzinga
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics ...
- GuruFocus.com
David Rolfe Adds 4 Stocks to Portfolio in 2nd Quarter
Guru’s largest new position is in telecom company Motorola Solutions Continue reading...
- Motley Fool
Alcon, Inc. (ALC) Q2 2019 Earnings Call Transcript
ALC earnings call for the period ending June 30, 2019.
- TheStreet.com
Charts of Alcon Look Good
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
- GuruFocus.com
Tweedy Browne Buys 2 Stocks, Adds to 3 in 2nd Quarter
Venerated value firm doubles stake in Baidu Continue reading...
